Why Structure Therapeutics Stock Was Stumbling This Week
Werte in diesem Artikel
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (NASDAQ: GPCR), was a victim of a general rout in the segment. According to data compiled by S&P Global Market Intelligence the company's share price had eroded by 11%, largely because of a single TV commercial.On Sunday, telehealth company and pharmaceutical retailer Hims & Hers Health splurged with a multimillion-dollar ad buy during the Super Bowl. The somewhat alarmist commercial -- "obesity is America's deadliest epidemic," intoned the narrator -- touted one of the higher-potential Hims & Hers' offerings, its compounded semaglutide weight loss treatment. Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Ausgewählte Hebelprodukte auf Structure Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Structure Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool
Nachrichten zu Structure Therapeutics Incorporation (spons. ADRs)
Analysen zu Structure Therapeutics Incorporation (spons. ADRs)
Keine Analysen gefunden.